NCT04216108 (23Gvs27G) is a NA clinical trial of Vitrectomy (23G gauge needle) in Vitreoretinal Surgery, sponsored by Prof. Dr. Peter Stalmans.

Who is sponsoring NCT04216108?

NCT04216108 is sponsored by Prof. Dr. Peter Stalmans.

What drugs are being tested in NCT04216108?

Interventions in NCT04216108: Vitrectomy (23G gauge needle), Vitrectomy (27G gauge needle).

What condition does NCT04216108 study?

NCT04216108 studies Vitreoretinal Surgery.

Is NCT04216108 still recruiting?

NCT04216108 is currently completed. Last updated 8 May 2020.

Last reviewed 2020-05-08 · How we verify

NCT04216108: 23Gvs27G

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparative Study 23G Versus 27G Vitrectomy

Completed NA Last updated 8 May 2020

What this trial tests

NA trial testing Vitrectomy (23G gauge needle) in Vitreoretinal Surgery in 80 participants. Completed in 13 March 2020.

Timeline

1 December 2018

Primary endpoint
5 March 2020

13 March 2020

Quick facts

Lead sponsor	Prof. Dr. Peter Stalmans
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	80
Start date	1 December 2018
Primary completion	5 March 2020
Estimated completion	13 March 2020
Sites	1 location across Belgium

Drugs / interventions tested

Vitrectomy (23G gauge needle)
Vitrectomy (27G gauge needle)

Conditions studied

Vitreoretinal Surgery — all drugs for Vitreoretinal Surgery →

Sponsor

Prof. Dr. Peter Stalmans

Who can join

18 and older, any sex, with Vitreoretinal Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigator-initiated, comparative double-arm, mono-center, prospective, interventional case study to determine whether ultra-small gauge surgery (27G gauge needle) improves postoperative outcome and patient morbidity.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Vitreoretinal Surgery

Currently open trials in the same condition.

NCT04371445 — Dextenza in the Post-op Management of Vitreoretinal Surgeries · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04216108 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Prof. Dr. Peter Stalmans
Last refreshed: 8 May 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04216108.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing